PurposeAlthough anti-hypertensive medications, including thiazides and beta-blockers (BBs) in particular, have been suggested to cause erectile dysfunction (ED) their real contribution is still conflicting. The aim of this paper is to summarize available evidence providing an evidence-based critical analysis of the topic.MethodsAn overall comprehensive narrative review was performed using Medline, Embase and Cochrane search. In addition, to better understand the impact of BBs on ED a specific systematic review was also performed.ResultsThe negative role of centrally acting drugs, such as clonidine and alpha-methyldopa, is well documented althuogh limited controlled trials are available. Angiotensin-converting enzyme inhibitors (ACEis), angiotensin receptor blockers (ARBs), and calcium-channel-blockers (CCBs) have neutral (CCBs) or even positive (ACEis and ARBs) effects on erectile function. Despite some preliminary negative reports, more recent evidence does not confirm the negative impact of thiazides. BBs should be still considered the class of medications more often associated with ED, although better outcomes can be drawn with nebivolol.ConclusionSexual function should be assessed in all patients with arterial hypertension, either at diagnosis or after the prescription of specific medications. A close related patient-physician interaction and discussion can overcome possible negative outcomes allowing a successful management of possible side effects.

Anti-hypertensive medications and erectile dysfunction: focus on β-blockers / Corona, G.; Vena, W.; Pizzocaro, A.; Salvio, G.; Sparano, C.; Sforza, A.; Maggi, M.. - In: ENDOCRINE. - ISSN 1559-0100. - ELETTRONICO. - (2024), pp. 0-0. [10.1007/s12020-024-04020-x]

Anti-hypertensive medications and erectile dysfunction: focus on β-blockers

Corona, G.;Sparano, C.;Maggi, M.
2024

Abstract

PurposeAlthough anti-hypertensive medications, including thiazides and beta-blockers (BBs) in particular, have been suggested to cause erectile dysfunction (ED) their real contribution is still conflicting. The aim of this paper is to summarize available evidence providing an evidence-based critical analysis of the topic.MethodsAn overall comprehensive narrative review was performed using Medline, Embase and Cochrane search. In addition, to better understand the impact of BBs on ED a specific systematic review was also performed.ResultsThe negative role of centrally acting drugs, such as clonidine and alpha-methyldopa, is well documented althuogh limited controlled trials are available. Angiotensin-converting enzyme inhibitors (ACEis), angiotensin receptor blockers (ARBs), and calcium-channel-blockers (CCBs) have neutral (CCBs) or even positive (ACEis and ARBs) effects on erectile function. Despite some preliminary negative reports, more recent evidence does not confirm the negative impact of thiazides. BBs should be still considered the class of medications more often associated with ED, although better outcomes can be drawn with nebivolol.ConclusionSexual function should be assessed in all patients with arterial hypertension, either at diagnosis or after the prescription of specific medications. A close related patient-physician interaction and discussion can overcome possible negative outcomes allowing a successful management of possible side effects.
2024
0
0
Corona, G.; Vena, W.; Pizzocaro, A.; Salvio, G.; Sparano, C.; Sforza, A.; Maggi, M.
File in questo prodotto:
File Dimensione Formato  
Corona G BB Endocrine 2024.pdf

accesso aperto

Tipologia: Pdf editoriale (Version of record)
Licenza: Open Access
Dimensione 2.05 MB
Formato Adobe PDF
2.05 MB Adobe PDF

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1394932
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact